Noriyuki Katsumata

Summary

Affiliation: National Center for Child Health and Development
Country: Japan

Publications

  1. ncbi request reprint Genetic defects in pregnenolone synthesis
    Noriyuki Katsumata
    Division of Basic Endocrine Research, Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
    Pediatr Endocrinol Rev 10:98-109. 2012
  2. ncbi request reprint Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
    Yuko Tanabe
    Department of Breast Oncology and Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 18:132-8. 2013
  3. doi request reprint A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer
    Mayu Yunokawa
    Department of Breast and Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 71:1369-74. 2013
  4. doi request reprint Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy
    Maki Tanioka
    National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 68:337-42. 2011
  5. doi request reprint A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer
    Kenji Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, 104 0045, Japan
    Med Oncol 28:434-40. 2011
  6. doi request reprint The notorious "drug lag" for oncology drugs in Japan
    Kan Yonemori
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, 103 0045, Japan
    Invest New Drugs 29:706-12. 2011
  7. doi request reprint The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors
    Kenji Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Urol Oncol 30:319-24. 2012
  8. doi request reprint A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)
    Isamu Saito
    Clinical Trial and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 40:90-3. 2010
  9. ncbi request reprint Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
  10. doi request reprint Feasibility and usefulness of the 'Distress Screening Program in Ambulatory Care' in clinical oncology practice
    Ken Shimizu
    Psycho Oncology Division, National Cancer Center Hospital, Chuou ku, Tokyo, Japan
    Psychooncology 19:718-25. 2010

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Genetic defects in pregnenolone synthesis
    Noriyuki Katsumata
    Division of Basic Endocrine Research, Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
    Pediatr Endocrinol Rev 10:98-109. 2012
    ..To define these conditions precisely, pathophysiological diagnoses, such as StAR deficiency and SCC deficiency, are more likely to be appropriate than the histopathological diagnosis like CLAH...
  2. ncbi request reprint Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer
    Yuko Tanabe
    Department of Breast Oncology and Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 18:132-8. 2013
    ..The long-term outcomes and risk factors of paclitaxel-induced peripheral neuropathy (PIPN) have not yet been fully elucidated...
  3. doi request reprint A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer
    Mayu Yunokawa
    Department of Breast and Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 71:1369-74. 2013
    ....
  4. doi request reprint Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy
    Maki Tanioka
    National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 68:337-42. 2011
    ..After the front-line platinum-based regimens including concurrent chemoradiotherapy (CCRT) in patients with advanced or recurrent cervical cancer, platinum-based regimens are often used again...
  5. doi request reprint A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer
    Kenji Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, 104 0045, Japan
    Med Oncol 28:434-40. 2011
    ..In patients failed to endocrine therapy, age and HER2 status were correlated to decision-making to choose chemotherapy...
  6. doi request reprint The notorious "drug lag" for oncology drugs in Japan
    Kan Yonemori
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, 103 0045, Japan
    Invest New Drugs 29:706-12. 2011
    ....
  7. doi request reprint The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors
    Kenji Hashimoto
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Urol Oncol 30:319-24. 2012
    ..The optimal management of extragonadal germ cell tumor (EGGCT) and metachronous testicular germ cell tumor (MTGCT) has not been determined...
  8. doi request reprint A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505)
    Isamu Saito
    Clinical Trial and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 40:90-3. 2010
    ..The primary endpoint is overall survival. Secondary endpoints are progression-free survival, response rates, adverse events, severe adverse events and the proportion of non-hospitalization periods compared with planned treatment periods...
  9. ncbi request reprint Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Lancet 374:1331-8. 2009
    ..Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer...
  10. doi request reprint Feasibility and usefulness of the 'Distress Screening Program in Ambulatory Care' in clinical oncology practice
    Ken Shimizu
    Psycho Oncology Division, National Cancer Center Hospital, Chuou ku, Tokyo, Japan
    Psychooncology 19:718-25. 2010
    ..This study assessed the feasibility and usefulness of the DISPAC program in actual clinical situations...
  11. doi request reprint An immunologically anomalous but considerably bioactive GH produced by a novel GH1 mutation (p.D116E)
    Sumito Dateki
    Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, 2 10 1 Ohkura, Setagaya, Tokyo 157 8535, Japan
    Eur J Endocrinol 161:301-6. 2009
    ..CONTEX: Although GH values measured by an immunoassay usually reflect GH bioactivities, discrepancy exists between immunoactivity and bioactivity in a rare condition known as 'bioinactive GH'...
  12. pmc Primary yolk sac tumor of the omentum: a case report and literature review
    Kenichi Harano
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Case Rep Oncol 5:671-5. 2012
    ..The present case suggests that IHC is a very useful diagnostic tool for subtyping CUP but should be interpreted in the context of clinical and morphological findings...
  13. doi request reprint Novel intronic CYP21A2 mutation in a Japanese patient with classic salt-wasting steroid 21-hydroxylase deficiency
    Noriyuki Katsumata
    Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157 8535, Japan
    Metabolism 59:1628-32. 2010
    ..In conclusion, the patient is a homozygote for the novel intronic IVS9-9C>A mutation, which affects messenger RNA splicing and totally inactivates 21-hydroxylase to give rise to clinically manifest classic salt-wasting 21-OHD...
  14. doi request reprint Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy
    Kan Yonemori
    Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Surg Oncol 101:222-7. 2010
    ....
  15. doi request reprint Novel CYP17A1 mutation in a Japanese patient with combined 17alpha-hydroxylase/17,20-lyase deficiency
    Noriyuki Katsumata
    Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo 157 8535, Japan
    Metabolism 59:275-8. 2010
    ....
  16. doi request reprint Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials
    Yasuo Ohashi
    Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan
    Cancer Sci 104:481-5. 2013
    ..No increase in thromboembolic events was observed in the ESA-treated patients (0.7% vs 1.7% placebo). The ESA reduced the risk of transfusion without a negative impact on the survival of patients with chemotherapy-induced anemia...
  17. pmc Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chem
    Noriyuki Katsumata
    Department of Medical Oncology, National Cancer Center, Tokyo, Japan
    Jpn J Clin Oncol 38:777-85. 2008
    ..This study was conducted to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in Japanese patients with Müllerian carcinoma having a therapeutic history of platinum-based chemotherapy...
  18. ncbi request reprint Novel missense mutation in the P-box of androgen receptor in a patient with androgen insensitivity syndrome
    Noriyuki Katsumata
    Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan
    Endocr J 55:225-8. 2008
    ....
  19. ncbi request reprint Nonclassic steroid 21-hydroxylase deficiency due to a homozygous V281L mutation in CYP21A2 detected by the neonatal mass-screening program in Japan
    Takashi Shinagawa
    Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan
    Endocr J 54:1021-5. 2007
    ....
  20. pmc Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer
    Yuuki Kuroda
    Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
    J Radiat Res 53:588-93. 2012
    ..9 vs 21.7%; P = 0.669). In conclusion, concurrent chemotherapy is valuable in definitive radiotherapy for Japanese women with FIGO IIIb cervical cancer...
  21. ncbi request reprint Uniparental disomy of chromosome 8 leading to homozygosity of a CYP11B1 mutation in a patient with congenital adrenal hyperplasia: Implication for a rare etiology of an autosomal recessive disorder
    Keiko Matsubara
    Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157 8535, Japan
    Endocr J 61:629-33. 2014
    ..Awareness of such rare cases should improve the accuracy of genetic counseling for families with CAH. Our data support the importance of UPD as an underlying mechanism of autosomal recessive disorders. ..
  22. ncbi request reprint Determination of biotin (vitamin H) by the high-performance affinity chromatography with a trypsin-treated avidin-bound column
    Kou Hayakawa
    Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan
    J Chromatogr B Analyt Technol Biomed Life Sci 869:93-100. 2008
    ..This affinity-chromatographic method for biotin determination was shown to be a robust and reliable and is well suited for biochemical and nutritional research...
  23. doi request reprint Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome
    Tadahiko Shien
    Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
    Breast Cancer Res Treat 113:307-13. 2009
    ..All three classifications analyzed were considered inadequate as the prognostic marker of the long-term outcome after NAC and further studies are warranted to optimize the prediction...
  24. ncbi request reprint The Third International Congress of the GRS and the IGF Society, November 11-15, 2006, Kobe, Japan
    Toshiaki Tanaka
    Department of Clinical Laboratory Medicine, National Center for Child Health and Development, Tokyo, Japan
    Pediatr Endocrinol Rev 4:362-5. 2007
  25. ncbi request reprint Replacement of alanine with asparagic acid at position 203 in human steroidogenic acute regulatory protein impairs the ability to enhance steroidogenesis in vitro
    Noriyuki Katsumata
    Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan
    Endocr J 53:427-31. 2006
    ..Together, these results indicate that the alanine at position 203 in human StAR is functionally important and that the D203 StAR is extremely unlikely to be a polymorphism...